Spero Therapeutics (SPRO) Sets New 1-Year Low at $10.58

Spero Therapeutics, Inc. (NASDAQ:SPRO)’s share price hit a new 52-week low on Thursday . The stock traded as low as $10.58 and last traded at $11.44, with a volume of 31800 shares changing hands. The stock had previously closed at $11.27.

SPRO has been the subject of several analyst reports. Stifel Nicolaus initiated coverage on Spero Therapeutics in a report on Monday, November 27th. They issued a “buy” rating and a $26.00 price objective for the company. Cowen initiated coverage on Spero Therapeutics in a report on Monday, November 27th. They issued an “outperform” rating for the company. Oppenheimer initiated coverage on Spero Therapeutics in a report on Monday, November 27th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Bank of America initiated coverage on Spero Therapeutics in a report on Monday, November 27th. They issued a “neutral” rating for the company.

In other news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of Spero Therapeutics stock in a transaction that occurred on Monday, November 6th. The shares were acquired at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Joel Sendek acquired 5,000 shares of Spero Therapeutics stock in a transaction that occurred on Monday, November 6th. The shares were purchased at an average price of $14.00 per share, for a total transaction of $70,000.00. The disclosure for this purchase can be found here. Insiders have bought a total of 649,356 shares of company stock valued at $9,090,984 in the last three months. 13.90% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: “Spero Therapeutics (SPRO) Sets New 1-Year Low at $10.58” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3080257/spero-therapeutics-spro-sets-new-1-year-low-at-10-58.html.

Spero Therapeutics Company Profile

SmartPros Ltd. is engaged in provision of learning and educational solutions in content areas that target specific markets, including accounting/finance, legal, engineering, securities and insurance. The Company also provides education in banking, finance, taxation, information technology, health and safety, human resources and compliance for the general corporate market.

Receive News & Ratings for Spero Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.